

Additional File 8

Endo-Lysosomal Proteins and Ubiquitin CSF Concentrations in Alzheimer's and Parkinson's Disease

Simon Sjödin^{1,2}, Gunnar Brinkmalm^{1,2}, Annika Öhrfelt^{1,2}, Lucilla Parnetti³, Silvia Paciotti⁴, Oskar Hansson^{5,6}, John Hardy⁷, Kaj Blennow^{1,2}, Henrik Zetterberg^{1,2,7,8}, Ann Brinkmalm^{1,2}

¹Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden

²Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden

³Neurology Clinic, University of Perugia, Perugia, Italy

⁴Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy

⁵Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden

⁶Memory Clinic, Skåne University Hospital, Malmö, Sweden

⁷Department of Molecular Neuroscience, University College London Institute of Neurology, Queen Square, London, UK

⁸UK Dementia Research Institute at UCL, London, United Kingdom

Corresponding Author: Simon Sjödin, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, House V3, SU/Mölndal, SE-43180, Mölndal, Sweden. simon.sjodin@neuro.gu.se.

Content

Figure S3

Figure S3. Significant peptides in Clinical Studies I and II. Peptides identified with a significantly different CSF concentration in either Clinical Study I or Clinical Study II, or both, are shown; (A) AP2B1_712-719, (B) AP2B1_835-842, (C) AP2B1_868-878 (the peptide was not measured in Clinical Study II), (D) C9_232-242, (E) CTSB_80-87, (F) CTSF_103-116, (G) CTSF_236-245, (H) CTSF_266-278, (I) CTSF_442-450, (J) GM2A_89-96, (K) GM2A_170-179, (L) LAMP1_357-363, (M) LAMP2_133-144, (N) LAMP2_153-161, (O) LAMP2_281-289, (P) TCN2_45-59, (Q) TCN2_300-313, (R) Ubiquitin_12-27, and (S) Ubiquitin_64-72. Clinical Study I (filled symbols) included cross-sectional samples from clinically characterized subjects with AD (N = 6) and PD (N = 10) as well as longitudinal samples from subjects with prodromal AD (N = 10) and stable MCI (N = 15). Clinical Study II (open symbols) included cross-sectional samples from clinically characterized subjects with AD (N = 36) and PD (N = 11) as well as cognitively normal healthy controls (N = 44). Statistics were calculated using Kruskal-Wallis test with Dunn's test for multiple comparisons comparing groups within the studies, not between, and the graphs show Tukey boxplots.

